Warning: Javascript must be enabled within your browser's settings for this site to function properly.

Your browser appears to be out of date, and is not supported by this site. For the best experience, we recommend that you upgrade to a more modern browser. You can find a list of modern browsers from www.browsehappy.com.

We use technical and analytics cookies data to ensure that we give you the best experience on our website. For more information visit our Privacy Page.

BWXT $   $  
As of . Minimum 20 minute delay.

News

BWXT Medical and Bayer AG Enter into Agreement for the Development and Production of Actinium-225

16 September 2021

(OTTAWA, Ontario – September 16, 2021) – BWX Technologies, Inc. (NYSE: BWXT) announced today that its BWXT Medical Ltd. subsidiary (BWXT Medical) has entered into an agreement with Bayer AG (Bayer) to develop Actinium-225 (Ac-225) supply and further partnering opportunities on finished products as both companies broaden their respective commercialization strategies for targeted radionuclide therapies (TRTs) and other innovative products.

Archive

Tags

Press Contacts:

BWX Technologies, Inc.

Jud Simmons 
+1 434.522.3800
hjsimmons@bwxt.com

BWXT Canada Ltd.  

Natalie Cutler 
+1 519.620.5288 
nacutler@bwxt.com 

BWXT Nuclear Energy Canada Inc.

Natalie Cutler
+1 519.620.5288  
nacutler@bwxt.com 

Nuclear Fuel Services, Inc.

Laura Bailey 
+1 423.743.9141
lebailey@nuclearfuelservices.com